 |
Vol.58 No.2 contents | Japanese/English |
 | Full Text of PDF (924K) Article in Japanese |
- Invited Review Article -
An Update of Companion Diagnostics for Lung Cancer
Taiki Hashimoto1, Noriko Motoi11Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Japan
With the recent progress in medical science, precision medicine is being implemented in cancer treatment to tailor medical treatments to individual characteristics. In the lung cancer field, several target therapies, including tyrosine kinase inhibitors for the treatment of EGFR, ALK, and ROS1-mutant non-small cell lung cancer, as well as PD-1/PD-L1 immune checkpoint inhibitors, have been administered to selected patients, based on the results of companion diagnostics. In this review, we provide an overview of the companion diagnostics for lung cancer in Japan and possible problems-mainly regarding quality control-from the perspective of pathologists.
key words: Lung cancer, Companion diagnostics, EGFR, ALK, PD-L1
JJLC 58 (2): 77-82, 2018
